Vertex Pharmaceuticals achieved positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, to treat moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions.   Treatment with VX-548 ...